BROMPERIDOL DECANOATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C31H41BrFNO3
Molecular Weight	574.565
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C3=CC=C(Br)C=C3

InChI

InChIKey=ZINCPWWBSRSXBH-UHFFFAOYSA-N

InChI=1S/C31H41BrFNO3/c1-2-3-4-5-6-7-8-11-30(36)37-31(26-14-16-27(32)17-15-26)20-23-34(24-21-31)22-9-10-29(35)25-12-18-28(33)19-13-25/h12-19H,2-11,20-24H2,1H3

HIDE SMILES / InChI

Description
Sources: http://www.scbt.com/datasheet-210966-bromperidol.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/23152208 | https://www.ncbi.nlm.nih.gov/pubmed/15266450 | https://www.ncbi.nlm.nih.gov/pubmed/23343447

Bromperidol decanoate is a long-acting antipsychotic medication used in at least Belgium, Germany, Italy, and the Netherlands. In clinical trials, Bromperidol decanoate was effective in the treatment of residual schizophrenia, with significant differences between before and after treatment ratings for symptoms. The preparation seems to be less potent than other depot antipsychotics (such as fluphenazine and haloperidol decanoate) and better than placebo injection. If bromperidol decanoate is available to the clinician it may be a viable choice, especially when there are reasons not to use fluphenazine or haloperidol decanoate.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine D2 receptor 297 Target ID: CHEMBL339 Sources: https://www.jstage.jst.go.jp/article/jphs1951/69/4/69_4_399/_article	Antagonist 2778
Dopamine D2 receptor 297 Target ID: CHEMBL217 Sources: https://www.genome.jp/dbget-bin/www_bget?D02626	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Schizophrenia 298 Sources: http://www.mimaki-family-japan.com/products/detail.php?product_id=32440	Primary		Approved 8429	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Clinical experiences in an open and a double-blind trial.	1978 Jan-Feb	347884
Double-blind- evaluation of bromperidol versus haloperidol treatment in chronic psychotic patients.	1978 Jan-Feb	347877
The initial US clinical experience in the management of schizophrenic patients with bromperidol.	1978 Jan-Feb	347876
Open study with bromperidol (C-C 2489), a new neuroleptic, for the determination of the neuroleptic threshold and the neuroleptic-therapeutic range.	1978 Mar	643910
Clinical evaluation of bromperidol versus haloperidol in psychotic patients.	1980	7021451
Possible interaction between cisapride and bromperidol.	1997 Jan	9075269
[Involvement of cytochromeP4503A4 in the metabolism of haloperidol and bromperidol].	1998 Feb	9592806
Lesioning the thalamus for dyskinesia.	2001	12378054
Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol.	2001 Apr 8	11353448
Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients.	2002 Apr	11999910
The characteristics of side-effects of bromperidol in schizophrenic patients.	2002 Feb	11929578
Switching to amisulpride due to hepatic complications.	2002 May	12052579
Depot bromperidol decanoate for schizophrenia.	2004	15266450
[Butyrophenone derivatives].	2004 Dec	15658342
Simultaneous determination of haloperidol and bromperidol and their reduced metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography.	2004 Jun 5	15113555
Influence of duration of untreated psychosis on auditory P300 in drug-naive and first-episode schizophrenia.	2005 Apr	15823170
Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects.	2005 Nov	16192844
Pharmacokinetic parameters of bromperidol in Korean subjects.	2006 Aug	16915578
Sensitive determination of 4-(4-bromophenyl)-4-hydroxypiperidine, a metabolite of bromperidol, in rat plasma by HPLC with fluorescence detection after pre-column derivatization using 4-fluoro-7-nitro-2,1,3-benzoxadiazole.	2006 Dec	17142985
Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study.	2006 Mar	16386826
Minimizing antipsychotic medication obviated the need for enema against severe constipation leading to paralytic ileus: a case report.	2007 Oct	17875120
Drugs associated with more suicidal ideations are also associated with more suicide attempts.	2009 Oct 2	19798416
Identification and quantification of 30 antipsychotics in blood using LC-MS/MS.	2010 Aug	20648676
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443
Screening of a chemical library reveals novel PXR-activating pharmacologic compounds.	2015 Jan 5	25455453

Patents

Sample Use Guides

In Vivo Use Guide

Oral Schizophrenia: Adult: 1-15 mg daily, up to 50 mg daily. Intramuscular Schizophrenia: Adult: Long-term therapy: Up to 300 mg every 4 wk via deep inj. Intramuscular Psychoses: Adult: Long-term therapy: Up to 300 mg every 4 wk via deep inj. Oral Psychoses: Adult: 1-15 mg daily, up to 50 mg daily.

Route of Administration: Other

In Vitro Use Guide

Bromperidol is able to antagonize as well as haloperidol the DA-induced LH-RH release.

Name

Type

Language

BROMPERIDOL DECANOATE

Official Name

English

BROMPERIDOL DECANOATE [USP-RS]

Common Name

English

BROMPERIDOL DECANOATE [MART.]

Common Name

English

4-(4-(P-BROMOPHENYL)-4-HYDROXYPIPERIDINOL)-4'-FLUOROBUTYROPHENONE DECANOATE

Common Name

English

DECANOIC ACID, 4-(4-BROMOPHENYL)-1-(4-(4-FLUOROPHENYL)-4-OXOBUTYL)-4-PIPERIDINYL ESTER

Common Name

English

R-46541

Code

English

BROMPERIDOL DECANOATE [EP MONOGRAPH]

Common Name

English

Bromperidol decanoate [WHO-DD]

Common Name

English

BROMPERIDOL DECANOATE (ESTER)

Common Name

English

BROMPERIDOL DECANOATE [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29710